Adalimumab

ApprovedTerminated

0 views this week 0 watching💤 Quiet

Interest: 35/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Axial Spondyloarthritis

Conditions

Axial Spondyloarthritis

Trial Timeline

Sep 12, 2016 → Dec 21, 2017

NCT ID

NCT02897115

About Adalimumab

Adalimumab is a approved stage product being developed by AbbVie for Axial Spondyloarthritis. The current trial status is terminated. This product is registered under clinical trial identifier NCT02897115. Target conditions include Axial Spondyloarthritis.

What happened to similar drugs?

5 of 20 similar drugs in Axial Spondyloarthritis were approved

Approved (5) Terminated (0) Active (15)

🔄Brodalumab + PlaceboKyowa KirinPhase 3

🔄Ixekizumab + PlaceboEli LillyPhase 3

🔄SHR0302 + SHR0302 placeboJiangsu Hengrui MedicinePhase 3

🔄Adalimumab + Placebo + Open-label AdalimumabAbbViePhase 3

🔄adalimumab + PlaceboAbbViePhase 3

🔄GolimumabMerckPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (20)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05414201	Approved	Completed	Jul 7, 2022	Jun 10, 2024	Non-infectious Intermediate Posterior- or Pan-uveitis
NCT04183608	Approved	Recruiting	Jan 14, 2020	May 1, 2028	Ulcerative Colitis
NCT03311464	Phase 3	Completed	Oct 27, 2017	Apr 21, 2020	Pyoderma Gangrenosum
NCT03261102	Pre-clinical	Active	Jan 17, 2017	Jun 1, 2025	Crohn Disease
NCT02897115	Approved	Terminated	Sep 12, 2016	Dec 21, 2017	Axial Spondyloarthritis
NCT02904902	Phase 3	Completed	Sep 6, 2016	May 30, 2019	Hidradenitis Suppurativa
NCT02668640	Pre-clinical	Completed	May 1, 2016	Aug 13, 2018	Rheumatoid Arthritis
NCT02750800	Pre-clinical	Completed	Apr 7, 2016	Apr 3, 2018	Rheumatoid Arthritis
NCT02739828	Pre-clinical	Completed	Apr 7, 2016	Mar 28, 2018	Hidradenitis Suppurativa
NCT02634541	Approved	UNKNOWN	Jan 1, 2016	Dec 1, 2017	Ankylosing Spondyloarthritis
NCT02632175	Phase 3	Completed	Nov 26, 2015	Apr 8, 2025	Ulcerative Colitis
NCT02533375	Phase 3	Completed	Sep 28, 2015	Jul 20, 2017	Generalized Pustular Psoriasis (GPP)
NCT02499783	Phase 3	Completed	Aug 17, 2015	Dec 15, 2017	Crohn's Disease
NCT02198651	Approved	Completed	Jan 5, 2015	Aug 8, 2018	Rheumatoid Arthritis
NCT02333383	Pre-clinical	Completed	Dec 31, 2014	Aug 8, 2017	Ankylosing Spondylitis
NCT02539849	Pre-clinical	Completed	Dec 1, 2014	Dec 19, 2017	Crohn Disease
NCT02185014	Phase 3	Completed	Aug 12, 2014	Nov 3, 2017	Crohn's Disease
NCT02148718	Approved	Completed	Jun 1, 2014	Jan 1, 2017	Moderate to Severe Crohn's Disease
NCT02065622	Phase 3	Completed	Mar 27, 2014	Nov 11, 2019	Ulcerative Colitis (UC)
NCT02016482	Phase 3	Completed	Jan 1, 2014	Apr 1, 2016	Nail Psoriasis

Competing Products

20 competing products in Axial Spondyloarthritis

See all competitors

Product	Company	Stage	Hype Score
SUNPG1622 I dose + Placebo dose	Sun Pharmaceutical	Phase 2	27
Brodalumab + Placebo	Kyowa Kirin	Phase 3	40
Ixekizumab + Placebo	Eli Lilly	Phase 3	40
Ixekizumab + Placebo	Eli Lilly	Phase 3	40
SHR0302 + SHR0302 placebo	Jiangsu Hengrui Medicine	Phase 3	36
SHR-1314	Jiangsu Hengrui Medicine	Phase 1	29
Upadacitinib	AbbVie	Pre-clinical	33
Adalimumab + Placebo + Open-label Adalimumab	AbbVie	Phase 3	40
adalimumab + Placebo	AbbVie	Phase 3	40
Treatment	Merck	Pre-clinical	66
Golimumab	Merck	Phase 3	40
Tulisokibart + Placebo	Merck	Phase 2	42
Secukinumab 150 milligram [Cosentyx]	Novartis	Approved	39
secukinumab	Novartis	Pre-clinical	26
Secukinumab + Placebo	Novartis	Phase 3	40
Secukinumab + Placebo + Secukinumab	Novartis	Approved	47
Secukinumab + Secukinumab and Placebo	Novartis	Phase 3	40
Secukinumab/Adalimumab-Biosimilar	Novartis	Phase 3	40
Brodalumab 210 mg + Placebo	Amgen	Phase 2	27
Etanercept 25mg + Sulfasalazine	Pfizer	Phase 2	31